Naviter Wealth LLC Buys 267 Shares of Danaher Co. (NYSE:DHR)

Naviter Wealth LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 3.2% during the third quarter, Holdings Channel.com reports. The fund owned 8,535 shares of the conglomerate’s stock after acquiring an additional 267 shares during the period. Naviter Wealth LLC’s holdings in Danaher were worth $2,375,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Tsfg LLC raised its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in Danaher in the second quarter valued at approximately $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DHR. Stifel Nicolaus raised their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Stephens started coverage on shares of Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Trading Up 2.4 %

DHR traded up $6.55 during trading on Thursday, hitting $274.58. The company’s stock had a trading volume of 451,238 shares, compared to its average volume of 2,707,988. The firm has a market capitalization of $203.38 billion, a P/E ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $270.53 and its 200-day moving average price is $259.65.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. Danaher’s revenue was down 2.9% on a year-over-year basis. Analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.